BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31648931)

  • 21. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
    Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF
    J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.
    Voss RK; Feng L; Lee JE; Perrier ND; Graham PH; Hyde SM; Nieves-Munoz F; Cabanillas ME; Waguespack SG; Cote GJ; Gagel RF; Grubbs EG
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2807-2813. PubMed ID: 28609830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medullary Thyroid Carcinoma: Survival Analysis and Evaluation of Mutation-Specific Immunohistochemistry in Detection of Sporadic Disease.
    Jayakody S; Reagh J; Bullock M; Aniss A; Clifton-Bligh R; Learoyd D; Robinson B; Delbridge L; Sidhu S; Gill AJ; Sywak M
    World J Surg; 2018 May; 42(5):1432-1439. PubMed ID: 29484475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
    de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
    Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cohort study on 10-year survival of sporadic medullary thyroid carcinoma with somatic RET mutation.
    Chuang LL; Hwang DY; Tsai KB; Chan HM; Chiang FY; Hsiao PJ
    Kaohsiung J Med Sci; 2016 Nov; 32(11):545-551. PubMed ID: 27847096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel RET mutations in macedonian patients with medullary thyroid carcinoma: genotype-phenotype correlations.
    Jovanovic R; Kostadinova-Kunovska S; Janevska V; Bogoeva B; Spasevska L; Miladinova D; Ugrinska A; Zdraveska-Kochovska M; Trajkov D; Petrusevska G
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):93-107. PubMed ID: 26076779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
    Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
    Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sporadic minute medullary thyroid carcinoma with a double RET mutation: A case report.
    Yamamoto H; Ishii J; Chiba T; Nakazato Y; Hirano K; Kamma H
    Pathol Int; 2017 Nov; 67(11):580-584. PubMed ID: 28952196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.
    Hanna GJ; Busaidy NL; Chau NG; Wirth LJ; Barletta JA; Calles A; Haddad RI; Kraft S; Cabanillas ME; Rabinowits G; O'Neill A; Limaye SA; Alexander EK; Moore FD; Misiwkeiwicz K; Thomas T; Nehs M; Marqusee E; Lee SL; Jänne PA; Lorch JH
    Clin Cancer Res; 2018 Apr; 24(7):1546-1553. PubMed ID: 29301825
    [No Abstract]   [Full Text] [Related]  

  • 30. Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells.
    Bertazza L; Barollo S; Radu CM; Cavedon E; Simioni P; Faggian D; Plebani M; Pelizzo MR; Rubin B; Boscaro M; Pezzani R; Mian C
    J Cell Mol Med; 2015 Sep; 19(9):2244-52. PubMed ID: 26081844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metastatic medullary thyroid carcinoma: a new way forward.
    Angelousi A; Hayes AR; Chatzellis E; Kaltsas GA; Grossman AB
    Endocr Relat Cancer; 2022 May; 29(7):R85-R103. PubMed ID: 35521769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New therapies in thyroid cancer].
    López Mondéjar P; Galofré JC
    Med Clin (Barc); 2016 Apr; 146(7):324-9. PubMed ID: 26723936
    [No Abstract]   [Full Text] [Related]  

  • 33. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
    Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
    Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sunitinib for the treatment of thyroid cancer.
    Gómez-Sáez JM
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1345-1352. PubMed ID: 27677828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EVOLUTION OF TARGETED THERAPIES FOR THYROID CARCINOMA.
    Sherman SI
    Trans Am Clin Climatol Assoc; 2019; 130():255-265. PubMed ID: 31516190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.
    Chu YH; Lloyd RV
    Endocr Pathol; 2016 Dec; 27(4):312-324. PubMed ID: 27539727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
    Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
    Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of neuroendocrine tumors in heterozygous mutant MENX rats: a novel model of invasive medullary thyroid carcinoma.
    Molatore S; Kügler A; Irmler M; Wiedemann T; Neff F; Feuchtinger A; Beckers J; Robledo M; Roncaroli F; Pellegata NS
    Endocr Relat Cancer; 2018 Feb; 25(2):145-162. PubMed ID: 29142006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study.
    Oczko-Wojciechowska M; Pfeifer A; Rusinek D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Kowal M; Swierniak M; Krajewska J; Gawlik T; Chmielik E; Czarniecka A; Szpak-Ulczok S; Jarząb B
    Endokrynol Pol; 2015; 66(2):121-5. PubMed ID: 25931041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
    Elisei R; Cosci B; Romei C; Bottici V; Renzini G; Molinaro E; Agate L; Vivaldi A; Faviana P; Basolo F; Miccoli P; Berti P; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2008 Mar; 93(3):682-7. PubMed ID: 18073307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.